Johnson & Johnson

Founded by three brothers, J&J began by mass-producing the world's first sterile surgical dressings and antiseptic products. At a time when hospital operations were plagued by lethal infections, the company turned medical hygiene into an industrial commodity. This early success established a culture of manufacturing excellence and safety that would allow the firm to become the default healthcare supplier for generations of doctors and families alike.

In 1982, seven people died after consuming Tylenol capsules that had been laced with cyanide by a criminal. In an industry-defining moment, J&J CEO James Burke took immediate, absolute responsibility, pulling 31 million bottles of Tylenol from store shelves nationwide. The transparency and swift action saved the brand, and the "Tylenol Crisis" became the global business school case study on how to handle an existential corporate threat while maintaining absolute integrity.

Recognizing that the slow-growth consumer business (Band-Aid, Listerine, Neutrogena) was dragging down the valuation of its high-growth medical device and pharmaceutical divisions, J&J initiated a monumental structural split. It began the multi-year process of spinning off its consumer health segment into an independent, publicly traded entity called Kenvue. This effectively transformed J&J into a pure-play, high-margin research and development powerhouse.

The successful IPO of Kenvue marked the completion of the most significant corporate restructuring in J&J's history. Free from the constraints of commodity consumer branding, the "new" J&J aggressively reinvested its capital into oncology, immunology, and complex robotic surgery. The pivot signaled to Wall Street that the 137-year-old firm was shedding its past to bet its future on high-end, complex therapeutic science.

By mid-2026, J&J stands as a concentrated, high-margin science giant, with revenue drivers focused on internal medical innovation rather than retail aisles. The firm dominates global markets in complex surgeries and specialized drugs, utilizing massive, automated R&D engines to maintain its competitive moat. It remains the most stable, institutionalized titan of the modern healthcare sector.